CEO: Thomas J. Schuetz, M.D., Ph.D.
Headquarters: Cambridge, Massachusetts
APO Financing: $60,500,000
At Compass, we take an unbiased approach to drug discovery by leveraging our proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through our StitchMabs™ and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability.
To date, we have drugged over 40 immune targets and generated a diverse pipeline of monoclonal and multi-specific therapeutic candidates with potential to transform care for patients with cancer or autoimmune diseases.